SequelSEC

Accustem Sciences Inc. ACUT

Pharmaceutical Preparations · CIK 0001850767 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$98.40K
Fiscal year ended 2026-06-30
Operating income
-$252.57K
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$9.68MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.60Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.01x1th

Accustem Sciences Inc. (ACUT) reported revenue of $98.40K and net income of -$252.57K for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Accustem Sciences Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Accustem Sciences Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$98.40K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$252.57K
Net income-$252.57K
Research & development$43.71K
Weighted-average diluted sharesshares 16.07M
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPS$-0.02
Selling, general & administrativeUnavailable
General & administrative$307.26K
Selling & marketingUnavailable

Balance

Accustem Sciences Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$1.61M
Current assets$106.20K
Total liabilities$5.72M
Current liabilities$5.72M
Total equity incl. NCI-$4.12M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$615.59K

Cash flow

Accustem Sciences Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flowUnavailable
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Accustem Sciences Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-256.7%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.02x
Revenue YoY growthUnavailable
Net margin-256.7%
R&D / revenue44.4%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ACUT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-14View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-20View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.